1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model
Mankash M, Kelly M, Dean J, Duffy A, Mehal W, Do A. 1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model. The American Journal Of Gastroenterology 2019, 114: s599-s599. DOI: 10.14309/01.ajg.0000593756.22484.ae.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseWeight loss medicationsNonalcoholic steatohepatitisBariatric surgeryWeight lossClinical characteristicsLiver diseaseObesity managementEffective treatmentDisease programsAverage age 55Meal replacement therapySurgical weight lossWeight loss optionsAlanine aminotransferase levelsChronic liver diseaseFatty liver diseaseObstructive sleep apneaManagement of patientsCare of patientsLimited efficacy dataClinical care modelsLiver disease modelAverage weight lossHepatology clinicIncorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis
Do A, Kuszewski EJ, Langberg K, Mehal W. Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. Hepatology 2019, 70: 1443-1456. PMID: 30991446, PMCID: PMC6783325, DOI: 10.1002/hep.30658.Peer-Reviewed Original ResearchConceptsTotal body weight lossWeight loss medicationsNonalcoholic steatohepatitisHepatology clinicStaging of NASHPartial histological responseBody weight lossHepatology practiceNASH histologyLiver histologyClinical profileLiver diseaseLiver triglyceridesNew medicationsClinical trialsHistological responseLifestyle changesPatientsMedicationsUncommonly resultsNatural historyClinical interventionsWeight lossSteatohepatitisHepatologists